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Background: Respiratory syncytial virus (RSV) infection
causes signiﬁcant morbidity and mortality in allogeneic
stem cell transplant (HCT) recipients. Although ribavirin
and immunoglobulin are key components of therapy, the
role of adjunct corticosteroids is not established. Corti-
costeroids may mitigate adverse pulmonary sequelae of
RSV infection, although they may also delay viral clear-
ance, and corticosteroid use has been included as a
negative factor in recent risk predictors of RSV mortality
(RSV ISI-Blood 2014).
Objectives: We sought to evaluate corticosteroid utilization
in the setting of post-HCT RSV infection in our center and
assess the association of corticosteroid use with morbidity
and mortality.
Methods: Patients with a history of RSV infection, seen at
Mayo Clinic Rochester from 2008 to 2014, were identiﬁed.
Treatment and outcome data were retrospectively collected.
Forced expiratory volume in one second (FEV1) and carbon
monoxide diffusion capacity (DLCO) were collected pre- and
post-RSV. Fisher’s exact test was used to compare categorical
variables.
Results: Details of therapy were extractable for 45 patients.
Twenty-one (47%) were on corticosteroids prior to RSV
diagnosis for treatment of graft versus host disease (GVHD).
Eleven (52%) of these patients had their steroid dose
increased by a median of 20 mg prednisone equivalents (PE).
An additional 8 (18%) patients were started on corticoste-
roids with median dosing of 62 mg PE. There was no differ-
ence in objective indices of RSV severity (RSV ISI) or baseline
prevalence of bronchiolitis obliterans (BO) between those
who did or did not receive corticosteroids. Dosing ranged
from 20 to 1250 mg/day PE. Most patients were started on
corticosteroids within 24 hours of RSV diagnosis and median
duration of use was 31 days. There was no difference in post-
RSV FEV1 (p¼0.4578) or DLCO (p¼0.4578) decline between
patients receiving corticosteroids and those who did not.
Sixteen (84%) patients who received corticosteroids were
hospitalized for a median length of 7.5 days (range 3-46),
compared to a 42% hospitalization rate for median of 6 days
(range 3-24) for those not receiving corticosteroids
(p¼0.0061). ICU admission was required in 9 (20%) patients
(8 received corticosteroids and 1 did not). Five (12%) patients
were receiving therapy for BO prior to RSV infection.
Following RSV infection, 11/30 (37%) long-term survivors
required therapy for BO, eight of whom had received
corticosteroids.
Conclusion: Adjunct corticosteroid use in the setting of RSV
infection appeared to be related to physician assessment of
disease acuity rather than objective indices of severity. Cor-
ticosteroids did not have any discernable effect on RSV-
related outcomes. The high ICU admission rate and need forlong-term BO therapy highlights the urgent need for better
RSV directed therapies.
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Background: High-dose etoposide (60 mg/kg) is used in
conditioning regimens for allogeneic stem cell trans-
plantation. As solubilizing excipients are present in
commercially available non-aqueous formulations (20 mg/
mL), dilution is needed before administration. Licensed ﬁnal
concentration ranges are 0.2-0.4 mg/mL, while crystalliza-
tion is likely to occur with concentrations higher than 0.4
mg/mL. Consequently, high-dose etoposide regimens require
huge quantities of dilution ﬂuids. So far, most centres use a
concentration of 1 mg/mL with limited stability of only one
hour which means a practical hurdle for pharmacists, nurses
and patients.
Aim: To deﬁne stability of etoposide (Sandoz) at a concen-
tration of 10.0mg/mL for 48h (5C) followed by 8h (25C)
(n¼3), at 25C for 24h.
Methodology and Results: Aspect was performed by visual
examination and the analytical assay by high performance
liquid chromatography according to the USP monograph.
Samples were stored for 48h at 5C with sampling testing
after 24h and 48h. Samples were consecutively stored for an
additional 8h at 25C (relative humidity of 60%) with sam-
pling and testing at the end of this extra storage period.
Sample dilutions stored at 25C/60% RH for 24h were
sampled and tested after 24h.
Visual aspects revealed a clear, colorless solution at all
test points for all dilutions. Evolution of the mean assay of
samples with regard to initial concentration at time zero (¼
100.0 %) revealed for t¼24h, 5C¼101.9%; t¼48h,
5C¼101.3%; t¼48h,5C + 8h,25C¼101.4%. For the samples
stored for 24h at 25C, a value of 104.2% was obtained.
Conclusion: Etoposide solutions of 10.0 mg/mL in NaCl
0.9% are stable when stored for 48h at 5C followed by
storage for 8h at 25C, and for 24h at 25C. Its use might
be an added-value for pharmacists, nurses and patients
during high-dose etoposide conditioning regimens.
Monitoring for hypotension and strict control of the
administration rate (below 10mg/kg/h) during infusion
remains necessary.
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Background: In recent years, hematopoietic stem cell
transplantation (HSCT) has emerged in pediatrics. Commu-
nity pharmacists (CP) are involved in the pharmacological
follow-up of these patients. This study aimed to explore the
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related to pediatric HSCT/oncology and to evaluate their
expectations in terms of training and education.
Methodology: An online questionnaire was set up (Qual-
trics) to evaluate knowledge and need for training. It con-
sisted of a general part, a part evaluating theoretical
knowledge on HSCT/pediatric oncology and some examples
to gain insight in the way they give pharmaceutical advice.
The ﬁnal part involved issues on past/present education.
Results: In total, 223 responses from 156 CP and 67 ST were
obtained. Of them, 26.3% (CP) and 11.9% (ST) were involved in
providing medication to this population. Only 34.0% (CP) and
44.0% (ST) gave correct answers to general questions. In total,
39.3% (CP and ST) had no idea how to handle this question or
to give advice (47.5%).
In total, 98.7% (CP) and 97.0% (ST) found the knowledge
they gained at the university insufﬁcient for their profes-
sional practice. None of CP and 4.5% (ST) had lessons on this
issue during their basic curriculum. Nevertheless, 68.6% (CP)
and 79.1% (ST) found it necessary to implement this subject
in the university curriculum. Finally, 91.0% (CP) and 89.6%
(ST) were voluntary to follow post-university education on
this subject (evening session or e-learning module).
Conclusion: Although the role of CP in pediatric HSCT/
oncology has been established, the results of this study show
a lack of knowledge and need for training. Both CP and ST are
interested in this subject and, apart from implementation in
the basic curriculum, they prefer evening sessions or e-
learning training to optimize their pharmaceutical care.537
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Introduction: Chemotherapy errors in the hematopoietic
stem cell transplant (HSCT) setting cause signiﬁcant
non-hematologic morbidity and mortality. The existing
“shame and blame” culture prevents error reporting, pro-
motes “work around” solutions, and fails to identify root
causes. The University of Virginia Health System imple-
mented LEAN principles and the A3 problem solving tool to
identify problems related to patient and employee safety,
and focus on system issues versus human error in order to
standardize work, eliminate waste and increases efﬁciency
of healthcare delivery.
Objective: To report the A3 analysis of a chemotherapy error
in which a HSCT patient scheduled for reduced intensity
ﬂudarabine/busulfan conditioning chemotherapy received
10 busulfan doses instead of the 8 intended.
Methods: Amultidisciplinary teamwas assembled including
a process coach. The A3 rigor was applied to: 1) Directly
observe the disciplines who provided the care then
visually illustrate the algorithm of the current state for the
ordering, veriﬁcation and administration of chemotherapy;
2) Identify the problem statement and associated violations
in Rules of Use (ﬁgure 1); 3) Identify the goal/target state;
4) Analyze to root cause by asking cascading “why”
questions starting with the problem statement; 5) Identify/
implement countermeasures to the root cause; 6) Measure
outcomes.
Results: The current condition is illustrated in ﬁgure 2.
Storm clouds indicate violations in Rules of Use. The
problem statement was “a patient received 2 unintended
doses of chemotherapy” and the identiﬁed root cause was
the use of a drug record not conﬁgured to the standard
treatment plan leading to the omission of therapy duration
(activity rule violation). Other contributing causes were
non-standard work and unclear communication regardings in Use
